Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, Muram D, Agnusdei D, Dowsett SA, Amewou-Atisso M, Cummings SR.

Breast Cancer Res Treat. 2012 Jul;134(1):299-306. doi: 10.1007/s10549-012-2041-5. Epub 2012 Apr 8.

PMID:
22484799
[PubMed - indexed for MEDLINE]
2.

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.

Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C.

J Bone Miner Res. 2011 Feb;26(2):397-404. doi: 10.1002/jbmr.191. Epub 2010 Jul 23.

PMID:
20658564
[PubMed - indexed for MEDLINE]
3.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
[PubMed - indexed for MEDLINE]
4.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
[PubMed - indexed for MEDLINE]
5.

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.

Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M.

J Clin Endocrinol Metab. 2009 Jul;94(7):2284-9. doi: 10.1210/jc.2008-2143. Epub 2009 Apr 7.

PMID:
19351734
[PubMed - indexed for MEDLINE]
6.

Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.

Goldstein SR, Bhattoa HP, Neven P, Cox DA, Dowsett SA, Alam J, Sipos A, Muram D.

Menopause. 2012 Jan;19(1):41-7. doi: 10.1097/gme.0b013e318223bbf4.

PMID:
21993078
[PubMed - indexed for MEDLINE]
7.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

PMID:
15572757
[PubMed - indexed for MEDLINE]
Free Article
8.

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.

Kendler DL, Palacios S, Cox DA, Stock J, Alam J, Dowsett SA, Zanchetta J.

Osteoporos Int. 2012 Mar;23(3):1091-101. doi: 10.1007/s00198-011-1587-0. Epub 2011 Mar 4.

PMID:
21374068
[PubMed - indexed for MEDLINE]
9.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC.

JAMA. 1999 Jun 16;281(23):2189-97. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10376571
[PubMed - indexed for MEDLINE]
10.

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial Investigators.

J Natl Cancer Inst. 2008 Jun 18;100(12):854-61. doi: 10.1093/jnci/djn153. Epub 2008 Jun 10.

PMID:
18544744
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10517716
[PubMed - indexed for MEDLINE]
12.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.

PMID:
10527181
[PubMed - indexed for MEDLINE]
13.

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R, Cummings SR, Eastell R, Ensrud KE, Goss P, Lee A, Neven P, Reid DM, Curto M, Vukicevic S; PEARL Investigators.

J Natl Cancer Inst. 2010 Nov 17;102(22):1706-15. doi: 10.1093/jnci/djq415. Epub 2010 Nov 4.

PMID:
21051656
[PubMed - indexed for MEDLINE]
Free Article
14.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

PMID:
16059623
[PubMed - indexed for MEDLINE]
15.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
[PubMed - indexed for MEDLINE]
16.

Predicting risk of breast cancer in postmenopausal women by hormone receptor status.

Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA; Women's Health Initiative Investigators.

J Natl Cancer Inst. 2007 Nov 21;99(22):1695-705. Epub 2007 Nov 13.

PMID:
18000216
[PubMed - indexed for MEDLINE]
Free Article
17.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators.

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

PMID:
21639806
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.

Osteoporos Int. 2009 Aug;20(8):1429-37. doi: 10.1007/s00198-008-0816-7. Epub 2008 Dec 20.

PMID:
19101754
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.

Downs RW Jr, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K.

Osteoporos Int. 2010 Jul;21(7):1215-26. doi: 10.1007/s00198-009-1060-5. Epub 2009 Oct 2.

PMID:
19798460
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk